Mary Meynardie

2Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York.

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy”.

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Cancer Research(2025)10.1158/0008-5472.can-25-0998

N/A

0.104DataRank · unranked

1 citations

Soumyadip Sahu, Minjie Zhang, Ayushi S. Patel, Ke Geng, Reshmee Bhattacharya +47 more

Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.03.014

N/A

0DataRank · unranked

12 citations

Christopher S. Nabel, Dezhi Li, Ruth Í. O’Connor, Caroline R. Crosby, Sarah Chang +27 more

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.18.537350

N/A

0DataRank · unranked

1 citations

David H. Peng, David Fenyö, Hao Yuan, Alfonso Lopez, Daniel Levin +26 more